Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,170 across all filing types
Latest filing 2025-02-11 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated February 12, 2025, from Lupin Limited, reporting unaudited financial results for the quarter and nine months ended December 31, 2024. It includes detailed financial highlights such as sales, EBITDA, PBT, PAT, segment sales, and operational highlights. The document is about quarterly financial performance and contains substantive financial data and analysis for Q3 FY2025. It is not a full annual report, audit report, or earnings release with only key highlights. The presence of detailed financial statements and analysis for a quarter indicates it is an Interim / Quarterly Report. The document is not a mere announcement or certification but contains actual financial data and management commentary on the quarter's performance. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2025
2025-02-11 English
Lupin Q3 FY2025 Results.
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated February 12, 2025, reporting unaudited financial results for Lupin Limited for the quarter and nine months ended December 31, 2024. It includes detailed financial highlights such as sales, EBITDA, PBT, PAT, segment sales, and operational highlights. The document is about quarterly financial performance and contains substantive financial data and analysis for a period shorter than a full fiscal year. It is not a full annual report, audit report, or earnings release with only key highlights. It is a comprehensive quarterly financial report with detailed financial statements and commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-02-11 English
Integrated Filing (Financial) for the quarter ended December 31, 2024.
Interim / Quarterly Report Classification · 100% confidence The document is an official filing addressed to the National Stock Exchange of India and BSE Limited, indicating compliance with SEBI regulations. It announces the unaudited financial results for the quarter and nine months ended December 31, 2024. The document includes a Limited Review Report by an independent auditor (B S R & Co. LLP) on the unaudited standalone financial results for the quarter and year-to-date period, prepared under Indian Accounting Standard 34 for Interim Financial Reporting. The presence of detailed financial data and the auditor's review report confirms this is a comprehensive interim financial report, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-02-11 English
Integrated Filing- Financial
Interim / Quarterly Report Classification · 100% confidence The document is an official filing addressed to the National Stock Exchange of India and BSE Limited, indicating compliance with SEBI regulations. It announces the unaudited financial results for the quarter and nine months ended December 31, 2024. The document includes a Limited Review Report by an independent auditor (B S R & Co. LLP) on the unaudited standalone financial results for the quarter and year-to-date period, prepared under Indian Accounting Standard 34 for Interim Financial Reporting. The presence of detailed financial data and the auditor's review report confirms this is a comprehensive interim financial report rather than a mere announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-02-11 English
General Updates
Board/Management Information Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting of Lupin Limited held on February 11, 2025. It details several board decisions including reappointments of whole-time directors, approval of a slump sale of a business segment to a wholly owned subsidiary, incorporation of a new subsidiary, and adoption of an employee stock option scheme. The document references compliance with SEBI Listing Regulations and includes detailed disclosures as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content focuses on board decisions and management changes rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full financial report, earnings release, or proxy statement. The primary purpose is to inform about board resolutions and related disclosures, which fits the category of Board/Management Information (MANG). The document length (15,000 characters) and detailed annexures support this classification rather than a brief announcement or report publication notice.
2025-02-11 English
Formulation, adoption and implementation of Lupin Employees Stock Option Scheme 2025 for grant of Employee Stock Options to the Eligible Employees of the Company and its subsidiaries under ....
Board/Management Information Classification · 95% confidence The document is an official announcement from Lupin Limited regarding the outcome of a Board Meeting held on February 11, 2025. It details the reappointment of key whole-time directors, the approval of a transfer of a business segment (Over-the-Counter Consumer Healthcare Business) to a wholly owned subsidiary, and the formulation of an employee stock option scheme. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes detailed disclosures as annexures. The content focuses on board decisions and management changes rather than financial results, audit opinions, or regulatory certifications. It is not a full financial report, earnings release, or proxy solicitation. The primary purpose is to inform stakeholders about board resolutions and management appointments, which fits the category of Board/Management Information (MANG). The document length (15,000 characters) and detailed disclosures support this classification rather than a brief announcement or a report publication notice.
2025-02-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.